

Evelyne Jacqz Aigrain

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4447612/publications.pdf>

Version: 2024-02-01

284
papers

8,731
citations

53660

45
h-index

71532

76
g-index

313
all docs

313
docs citations

313
times ranked

7338
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial. <i>The Lancet Child and Adolescent Health</i> , 2022, 6, 49-59.	2.7	7
2	How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	1.1	3
3	Pharmacokinetics of mycophenolic acid and external evaluation of two limited sampling strategies of drug exposure in patients with juvenile systemic lupus erythematosus. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 1003-1010.	0.8	3
4	A loss-of-function <i>IFNAR1</i> allele in Polynesia underlies severe viral diseases in homozygotes. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	28
5	Predictive Performance of Pharmacokinetic Model-Based Virtual Trials of Vancomycin in Neonates: Mathematics Matches Clinical Observation. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1027-1038.	1.6	4
6	Analysis of Paediatric Clinical Trial Characteristics and Activity Over 23 Yearsâ€”Impact of the European Paediatric Regulation on a Single French Clinical Research Center. <i>Frontiers in Pediatrics</i> , 2022, 10, 842480.	0.9	0
7	Developmental population pharmacokinetics of caffeine in Chinese premature infants with apnoea of prematurity: A postâ€”marketing study to support paediatric labelling in China. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1155-1164.	1.1	11
8	Extremely low dose of 6â€”mercaptopurine in a Chinese child with acute lymphoblastic leukaemia and multiple pharmacogenetic mutations. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 74-77.	0.7	1
9	Population pharmacokinetics and dosing optimization of azlocillin in neonates with early-onset sepsis: a real-world study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 699-709.	1.3	11
10	Relationship between adverse drug reactions and unlicensed/off-label drug use in hospitalized children (EREMI): A study protocol. <i>Therapie</i> , 2021, 76, 675-685.	0.6	7
11	Paediatric clinical research in Europe: an insight on expertsâ€™ needs and perspectives. <i>Contemporary Clinical Trials Communications</i> , 2021, 21, 100735.	0.5	5
12	Serum Creatinine and Serum Cystatin C are Both Relevant Renal Markers to Estimate Vancomycin Clearance in Critically Ill Neonates. <i>Frontiers in Pharmacology</i> , 2021, 12, 634686.	1.6	4
13	Simplified Dosing Regimens for Gentamicin in Neonatal Sepsis. <i>Frontiers in Pharmacology</i> , 2021, 12, 624662.	1.6	1
14	Contribution of Population Pharmacokinetics of Glycopeptides and Antifungals to Dosage Adaptation in Paediatric Onco-hematological Malignancies: A Review. <i>Frontiers in Pharmacology</i> , 2021, 12, 635345.	1.6	1
15	A Consensus-Based Checklist for Reporting of Survey Studies (CROSS). <i>Journal of General Internal Medicine</i> , 2021, 36, 3179-3187.	1.3	575
16	Drug Clearance in Neonates: A Combination of Population Pharmacokinetic Modelling and Machine Learning Approaches to Improve Individual Prediction. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1435-1448.	1.6	20
17	Drug Safety in Translational Paediatric Research: Practical Points to Consider for Paediatric Safety Profiling and Protocol Development: A Scoping Review. <i>Pharmaceutics</i> , 2021, 13, 695.	2.0	4
18	Tacrolimus Bayesian Dose Adjustment in Pediatric Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 472-480.	1.0	7

#	ARTICLE	IF	CITATIONS
19	Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 274-284.	1.1	7
20	Pharmacokinetics of pitolisant in children and adolescents with narcolepsy. <i>Sleep Medicine</i> , 2020, 66, 220-226.	0.8	17
21	Population pharmacokinetics and dose optimization of ceftriaxone for children with community-acquired pneumonia. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1547-1556.	0.8	6
22	Developmental population pharmacokinetics and pharmacodynamics and dosing optimization of cefoperazone in children. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1917-1924.	1.3	6
23	Population pharmacokinetics of ceftazidime in critically ill children: impact of cystic fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2232-2239.	1.3	4
24	Precision therapy of 6-mercaptopurine in Chinese children with acute lymphoblastic leukaemia. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1519-1527.	1.1	13
25	Reporting of offspring data in diabetes, HIV infection and hypertension trials during pregnancy: a systematic review. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2020, 105, 215-221.	1.4	1
26	An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 329.	0.7	6
27	Informed consent for neonatal trials: practical points to consider and a check list. <i>BMJ Paediatrics Open</i> , 2020, 4, e000847.	0.6	7
28	Characteristics of prescription in 29 Level 3 Neonatal Wards over a 2-year period (2017-2018). An inventory for future research. <i>PLoS ONE</i> , 2019, 14, e0222667.	1.1	23
29	Melatonin Levels in Preterm and Term Infants and Their Mothers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2077.	1.8	35
30	Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2128-2138.	1.3	33
31	UPLC/MS/MS assay for the simultaneous determination of seven antibiotics in human serum: Application to pediatric studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 174, 256-262.	1.4	19
32	Body Surface Area-Based Dosing Regimen of Caspofungin in Children: a Population Pharmacokinetics Confirmatory Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	4
33	Population Pharmacokinetics and Dosing Optimization of Imipenem in Children with Hematological Malignancies. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	8
34	P30...Limited sampling strategies to predict valganciclovir exposure in kidney transplanted children. <i>Archives of Disease in Childhood</i> , 2019, 104, e29.2-e29.	1.0	0
35	P60...Serum Creatinine is superior to Serum Cystatin C in explaining inter-individual variability of vancomycin clearance in neonates and young infants. <i>Archives of Disease in Childhood</i> , 2019, 104, e42.1-e42.	1.0	0
36	<p>Developmental Pharmacogenetics of SLCO2B1 on Montelukast Pharmacokinetics in Chinese Children</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 4405-4411.	2.0	3

#	ARTICLE	IF	CITATIONS
37	Population Pharmacokinetics of Ganciclovir after Valganciclovir Treatment in Children with Renal Transplant. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	15
38	Ophthalmic Insert versus Eye Drops for Mydriasis in Neonates: A Randomized Clinical Trial. <i>Neonatology</i> , 2019, 115, 142-148.	0.9	5
39	Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Neonates and Young Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	29
40	<scp>mRNA</scp> expression of drug metabolism enzymes and transporter genes at birth using human umbilical cord blood. <i>Fundamental and Clinical Pharmacology</i> , 2018, 32, 422-435.	1.0	3
41	Pilot Study of Model-Based Dosage Individualization of Ganciclovir in Neonates and Young Infants with Congenital Cytomegalovirus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	12
42	Drug evaluation in children 10 years after the European pediatric regulation current challenges and perspectives. <i>Therapie</i> , 2018, 73, 113-117.	0.6	6
43	Pharmacogenetics and application in pediatrics. <i>Therapie</i> , 2018, 73, 157-163.	0.6	3
44	Population pharmacokinetics of tacrolimus in children with nephrotic syndrome. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1748-1756.	1.1	27
45	Sequential analysis in neonatal researchâ€”systematic review. <i>European Journal of Pediatrics</i> , 2018, 177, 733-740.	1.3	3
46	Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus. <i>Pediatric Nephrology</i> , 2018, 33, 1045-1055.	0.9	10
47	Penetration of Cefotaxime into Cerebrospinal Fluid in Neonates and Young Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	7
48	Developmental pharmacogenetics of <scp>CYP2C19</scp> in neonates and young infants: omeprazole as a probe drug. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 997-1005.	1.1	16
49	Population Pharmacokinetics of Cefotaxime and Dosage Recommendations in Children with Sickle Cell Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	11
50	Population Pharmacokinetics and Dosing Optimization of Ceftazidime in Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	20
51	Capacities and Competences for Drug Evaluation in European Neonatal Intensive Care Units: A Survey and Key Issues for Improvement. <i>American Journal of Perinatology</i> , 2018, 35, 589-598.	0.6	1
52	Principles and applications of pharmacometrics in drug evaluation in children. <i>Therapie</i> , 2018, 73, 165-170.	0.6	3
53	Off-label use of tacrolimus in children with Henoch-SchÅ¼nlein purpura nephritis: a pilot study. <i>Archives of Disease in Childhood</i> , 2018, 103, 772-775.	1.0	10
54	Adverse Events under Tacrolimus and Cyclosporine in the First 3 Years Post-Renal Transplantation in Children. <i>Clinical Drug Investigation</i> , 2018, 38, 157-171.	1.1	9

#	ARTICLE	IF	CITATIONS
55	Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 358-368.	1.1	25
56	Variability of ciprofloxacin pharmacokinetics in children: impact on dose range in sickle cell patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3423-3429.	1.3	7
57	Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	12
58	Pharmacogenetics: Applications to Pediatric Patients. <i>Advances in Pharmacology</i> , 2018, 83, 191-215.	1.2	5
59	Early target attainment of azithromycin therapy in children with lower respiratory tract infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2846-2850.	1.3	8
60	Clinical trials in neonates: How to optimise informed consent and decision making? A European Delphi survey of parent representatives and clinicians. <i>PLoS ONE</i> , 2018, 13, e0198097.	1.1	15
61	Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1989-1999.	1.1	26
62	Population pharmacokinetics and dosing optimization of cefthiamidine in children with hematologic infection. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 855-862.	2.0	4
63	Aciclovir CSF concentration in children with viral encephalitis: is it adequate?. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2582-2583.	1.3	0
64	Transethnic, Genome-Wide Analysis Reveals Immune-Related Risk Alleles and Phenotypic Correlates in Pediatric Steroid-Sensitive Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2000-2013.	3.0	72
65	Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1287-1297.	1.1	8
66	Licensed medicines, off-label use or evidence-based. Which is most important?. <i>Archives of Disease in Childhood</i> , 2017, 102, 53-54.	1.0	17
67	High Prevalence of Polycystic Ovary Syndrome in Type 1 Diabetes Mellitus Adolescents: Is There a Difference Depending on the NIH and Rotterdam Criteria?. <i>Hormone Research in Paediatrics</i> , 2017, 87, 333-341.	0.8	15
68	Pharmacogenetics of posttransplant diabetes mellitus. <i>Pharmacogenomics Journal</i> , 2017, 17, 209-221.	0.9	5
69	A Computer Prescribing Order Entry-Clinical Decision Support system designed for neonatal care: results of the "preselected prescription" concept at the bedside. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 64-68.	0.7	14
70	Growth Outcomes After GH Therapy of Patients Given Long-Term Corticosteroids for Juvenile Idiopathic Arthritis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4578-4587.	1.8	5
71	Les bases de pharmacologie du développement. , 2017, , 43-48.		0
72	Drug versus placebo randomized controlled trials in neonates: A review of ClinicalTrials.gov registry. <i>PLoS ONE</i> , 2017, 12, e0171760.	1.1	4

#	ARTICLE	IF	CITATIONS
73	Population Pharmacokinetics of Cefotaxime and Dosage Recommendations in Children with Sickle Cell Disease. <i>Blood</i> , 2017, 130, 975-975.	0.6	1
74	PHARMACOKINETIC STUDIES IN NEONATES: IS AN OPPORTUNISTIC SAMPLING STRATEGY SUFFICIENT FOR POPULATION PHARMACOKINETIC MODELLING AND DOSE PREDICTION?. <i>Archives of Disease in Childhood</i> , 2016, 101, e1.11-e1.	1.0	0
75	Dose-Finding Study of Omeprazole on Gastric pH in Neonates with Gastro-Esophageal Acid Reflux Using a Bayesian Sequential Approach. <i>PLoS ONE</i> , 2016, 11, e0166207.	1.1	9
76	Neonatal adverse drug reactions: an analysis of reports to the French pharmacovigilance database. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1058-1068.	1.1	16
77	RISK FACTORS FOR NODAT UNDER IMMUNOSSUPPRESSANTS IN RENAL TRANSPLANTED CHILDREN. <i>Archives of Disease in Childhood</i> , 2016, 101, e1.44-e1.	1.0	0
78	A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6626-6634.	1.4	26
79	A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate. <i>Hormone Research in Paediatrics</i> , 2016, 86, 188-195.	0.8	10
80	Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats. <i>Antiviral Research</i> , 2016, 132, 111-115.	1.9	9
81	PEDIATRIC DRUG TRIALS IN CHINA. <i>Archives of Disease in Childhood</i> , 2016, 101, e1.12-e1.	1.0	0
82	THE CLINICAL UTILITY AND SAFETY OF A MODEL-BASED PATIENT-TAILORED DOSE REGIMEN OF VANCOMYCIN IN NEONATES. <i>Archives of Disease in Childhood</i> , 2016, 101, e1.37-e1.	1.0	0
83	NEONATAL ADVERSE DRUG REACTIONS: ANALYSIS OF PHARMACOVIGILANCE REPORTS AFTER DIRECT DRUG EXPOSURE IN FRANCE. <i>Archives of Disease in Childhood</i> , 2016, 101, e1.22-e1.	1.0	0
84	Safety study of Ciprofloxacin in newborn mice. <i>Regulatory Toxicology and Pharmacology</i> , 2016, 74, 161-169.	1.3	15
85	Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 992-1002.	1.3	37
86	Evaluation of a pediatric liquid formulation to improve 6-mercaptopurine therapy in children. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 83, 1-7.	1.9	9
87	Clinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2039-2042.	1.4	44
88	DO WE HAVE A CONSENSUS TO APPLY MODEL-BASED AMINOGLYCOSIDE THERAPY: A REVIEW OF POPULATION PHARMACOKINETIC MODELS. <i>Archives of Disease in Childhood</i> , 2016, 101, e1.51-e1.	1.0	0
89	Use and safety of azithromycin in neonates: a systematic review. <i>BMJ Open</i> , 2015, 5, e008194.	0.8	46
90	Author's Reply to Standing et al. Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1289-1291.	1.6	2

#	ARTICLE	IF	CITATIONS
91	Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1197-1207.	1.1	41
92	Pharmacologie des anti-infectieux en pédiatrie néonatale. , 2015, , 187-196.		0
93	Approches méthodologiques en pharmacogénétique: le modèle des leucémies aiguës lymphoblastiques de l'enfant. <i>Revue D'Oncologie Hématologie Pédiatrique</i> , 2015, 3, 215-220.	0.1	0
94	Fluconazole prophylaxis in neonates. <i>Archives of Disease in Childhood</i> , 2015, 100, 75-76.	1.0	6
95	Cystatin C as a potential biomarker for dosing of renally excreted drugs. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 20-27.	1.1	25
96	Successful private-public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines. <i>European Journal of Pediatrics</i> , 2015, 174, 481-491.	1.3	30
97	Therapeutic guidelines for prescribing antibiotics in neonates should be evidence-based: a French national survey. <i>Archives of Disease in Childhood</i> , 2015, 100, 394-398.	1.0	65
98	Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1273-1285.	1.6	65
99	Choosing the right dose of tacrolimus. <i>Archives of Disease in Childhood</i> , 2015, 100, 406-413.	1.0	29
100	Gastrointestinal tolerance of erythritol-containing beverage in young children: a double-blind, randomised controlled trial. <i>European Journal of Clinical Nutrition</i> , 2015, 69, 746-751.	1.3	14
101	How to use vancomycin optimally in neonates: remaining questions. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 635-648.	1.3	28
102	Ophthalmic insert for pupillary mydriasis in neonates. <i>Acta Ophthalmologica</i> , 2015, 93, n/a-n/a.	0.6	0
103	Ophthalmic insert for pupillary mydriasis in neonates. <i>Acta Ophthalmologica</i> , 2015, 93, n/a-n/a.	0.6	0
104	Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder. <i>Drug Design, Development and Therapy</i> , 2014, 8, 2321.	2.0	8
105	An optimal LC-MS/MS method for determination of azithromycin in white blood cells: application to pediatric samples. <i>Bioanalysis</i> , 2014, 6, 2317-2328.	0.6	6
106	Neonatal drug trials: impact of EU and US paediatric regulations. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2014, 99, F438-F438.	1.4	19
107	First Dose in Neonates: Are Juvenile Mice, Adults and In Vitro In Silico Data Predictive of Neonatal Pharmacokinetics of Fluconazole. <i>Clinical Pharmacokinetics</i> , 2014, 53, 1005-1018.	1.6	14
108	Population Pharmacokinetics of Ciprofloxacin in Neonates and Young Infants Less than Three Months of Age. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6572-6580.	1.4	41

#	ARTICLE	IF	CITATIONS
109	Covariate effects and population pharmacokinetics of lamivudine in <scp>HIV</scp>-infected children. British Journal of Clinical Pharmacology, 2014, 77, 861-872.	1.1	17
110	A model-based approach for the evaluation of once daily dosing of lamivudine in <scp>HIV</scp>-infected children. British Journal of Clinical Pharmacology, 2014, 77, 852-860.	1.1	6
111	Association Between Pulmonary Ureaplasma Colonization and Bronchopulmonary Dysplasia in Preterm Infants. Pediatric Infectious Disease Journal, 2014, 33, 697-702.	1.1	84
112	Population Pharmacokinetics and Dosing Optimization of Vancomycin in Children with Malignant Hematological Disease. Antimicrobial Agents and Chemotherapy, 2014, 58, 3191-3199.	1.4	62
113	Pharmacokinetics and dosage individualization of ganciclovir and valganciclovir in an infant with nephrotic syndrome associated with cytomegalovirus infection. Journal of Antimicrobial Chemotherapy, 2014, 69, 1150-1151.	1.3	6
114	Dosage individualization in children: integration of pharmacometrics in clinical practice. World Journal of Pediatrics, 2014, 10, 197-203.	0.8	14
115	Prevalence of herpesviruses at onset of idiopathic nephrotic syndrome. Pediatric Nephrology, 2014, 29, 2325-2331.	0.9	37
116	Ureaplasma, bronchopulmonary dysplasia and azithromycin in European neonatal intensive care units: a survey. Scientific Reports, 2014, 4, 4076.	1.6	7
117	A Delphi Process to Optimize Quality and Performance of Drug Evaluation in Neonates. PLoS ONE, 2014, 9, e104976.	1.1	10
118	Impact of Glutathione S-Transferase M1 and T1 on Anti-Tuberculosis Drug-Induced Hepatotoxicity in Chinese Pediatric Patients. PLoS ONE, 2014, 9, e115410.	1.1	17
119	Limited sampling strategy using Bayesian estimation for estimating individual exposure of the once-daily prolonged-release formulation of tacrolimus in kidney transplant children. European Journal of Clinical Pharmacology, 2013, 69, 1181-1185.	0.8	13
120	Wide intra- and inter-country variability in drug use and dosage in very-low-birth-weight newborns with severe infections. European Journal of Clinical Pharmacology, 2013, 69, 1031-1036.	0.8	15
121	A Novel Maturation Function for Clearance of the Cytochrome P450 3A Substrate Midazolam from Preterm Neonates to Adults. Clinical Pharmacokinetics, 2013, 52, 555-565.	1.6	41
122	Recruitment in pediatric clinical research was influenced by study characteristics and pediatricians' perceptions: a multicenter survey. Journal of Clinical Epidemiology, 2013, 66, 1151-1157.	2.4	20
123	Amikacin Maturation Model as a Marker of Renal Maturation to Predict Glomerular Filtration Rate and Vancomycin Clearance in Neonates. Clinical Pharmacokinetics, 2013, 52, 1127-1134.	1.6	29
124	Population pharmacokinetics of abacavir in infants, toddlers and children. British Journal of Clinical Pharmacology, 2013, 75, 1525-1535.	1.1	13
125	TINN (TREAT INFECTIONS IN NEONATES): AN FP7 PROJECT. Clinical Therapeutics, 2013, 35, e118-e119.	1.1	0
126	Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. Seminars in Fetal and Neonatal Medicine, 2013, 18, 28-34.	1.1	59

#	ARTICLE	IF	CITATIONS
127	Safety of fluconazole in paediatrics: a systematic review. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1211-1221.	0.8	34
128	Randomized controlled trials of antibiotics for neonatal infections: a systematic review. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 21-29.	1.1	13
129	Effects of Recombinant Human Growth Hormone for 1 Year on Body Composition and Muscle Strength in Children on Long-Term Steroid Therapy: Randomized Controlled, Delayed-Start Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2746-2754.	1.8	11
130	Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 189-195.	0.8	56
131	Population pharmacokinetics of ciclosporin in Chinese children with aplastic anemia: effects of weight, renal function and stanozolol administration. <i>Acta Pharmacologica Sinica</i> , 2013, 34, 969-975.	2.8	13
132	Prevention of Nosocomial Infections in Neonatal Intensive Care Units. <i>American Journal of Perinatology</i> , 2013, 30, 081-088.	0.6	62
133	External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1068-1080.	1.1	92
134	Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. <i>Archives of Disease in Childhood</i> , 2013, 98, 449-453.	1.0	104
135	The Importance of Knowing How Vancomycin is Measured When Interpreting Its Pharmacokinetic Results. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 416.	1.0	8
136	Triazole Use in the Nursery: Fluconazole, Voriconazole, Posaconazole, and Ravuconazole. <i>Current Drug Metabolism</i> , 2013, 14, 193-202.	0.7	1
137	Echinocandins for the Nursery: An Update. <i>Current Drug Metabolism</i> , 2013, 14, 203-207.	0.7	2
138	Azithromycin, <i>Ureaplasma</i> and chronic lung disease of prematurity: a case study for neonatal drug development: Figure 1. <i>Archives of Disease in Childhood</i> , 2012, 97, 573-577.	1.0	14
139	Pharmacogenetic Determinant of the Drug Interaction Between Tacrolimus and Omeprazole. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 739-741.	1.0	13
140	Individualization of Valganciclovir Prophylaxis for Cytomegalovirus Infection in Pediatric Kidney Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 326-330.	1.0	21
141	Editorial Commentary: Effectiveness or Efficacy: Which Study to Evaluate Antibiotics in Neonates?. <i>Clinical Infectious Diseases</i> , 2012, 55, 1503-1504.	2.9	1
142	Intracellular Disposition of Methotrexate in Acute Lymphoblastic Leukemia in Children. <i>Current Drug Metabolism</i> , 2012, 13, 822-834.	0.7	39
143	1325 Intra-Subject Variability on 3T MRI Imaging of Neonatal Hips. <i>Archives of Disease in Childhood</i> , 2012, 97, A377-A378.	1.0	0
144	Pharmacokinetic Interaction Between Tacrolimus and Amlodipine in a Renal Transplant Child. <i>Transplantation</i> , 2012, 93, e29-e30.	0.5	12

#	ARTICLE	IF	CITATIONS
145	Optimizing Micafungin Dosing in Children. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 1211-1212.	1.1	5
146	How to Optimize the Evaluation and Use of Antibiotics in Neonates. <i>Pediatric Clinics of North America</i> , 2012, 59, 1117-1128.	0.9	8
147	Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1233-1242.	0.8	49
148	Physiopathology of idiopathic nephrotic syndrome: lessons from glucocorticoids and epigenetic perspectives. <i>Pediatric Nephrology</i> , 2012, 27, 1249-1256.	0.9	44
149	Neonatal fungal infections: when to treat?. <i>Early Human Development</i> , 2012, 88, S6-S10.	0.8	47
150	Fluconazole use and safety in the nursery. <i>Early Human Development</i> , 2012, 88, S11-S15.	0.8	18
151	Clinical characteristics and response to prophylactic fluconazole of preterm VLBW neonates with baseline and acquired fungal colonisation in NICU: data from a multicentre RCT. <i>Early Human Development</i> , 2012, 88, S60-S64.	0.8	16
152	Neonatal cutaneous disseminated aspergillosis in a preterm extremely-low-birth-weight infant with favourable outcome at 3-year follow-up: a case report. <i>Early Human Development</i> , 2012, 88, S65-S68.	0.8	7
153	Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units. <i>Early Human Development</i> , 2012, 88, S69-S74.	0.8	382
154	Sepsis in young infants with congenital heart disease. <i>Early Human Development</i> , 2012, 88, S92-S97.	0.8	24
155	Correct choices for correct treatments: key issues in the management of <i>Candida</i> infections in preterm neonates. <i>Early Human Development</i> , 2012, 88, S98-S100.	0.8	8
156	Population pharmacokinetics and maximum <i>a posteriori</i> probability Bayesian estimator of abacavir: application of individualized therapy in HIV-1 infected infants and toddlers. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 641-650.	1.1	10
157	European survey on the use of prophylactic fluconazole in neonatal intensive care units. <i>European Journal of Pediatrics</i> , 2012, 171, 439-445.	1.3	32
158	Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial. <i>Pediatric Nephrology</i> , 2012, 27, 389-396.	0.9	48
159	<i>Candida</i> colonization in the nursery. <i>Jornal De Pediatria</i> , 2012, 88, 187-90.	0.9	8
160	Ciprofloxacin safety in paediatrics: a systematic review. <i>Archives of Disease in Childhood</i> , 2011, 96, 874-880.	1.0	137
161	The management of <i>Candida</i> infections in preterm neonates and the role of micafungin. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2011, 24, 24-27.	0.7	21
162	Ciprofloxacin Use in Neonates. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, e29-e37.	1.1	67

#	ARTICLE	IF	CITATIONS
163	Maternal Immune Response and Neonatal Seroprotection From a Single Dose of a Monovalent Nonadjuvanted 2009 Influenza A(H1N1) Vaccine. <i>Annals of Internal Medicine</i> , 2011, 155, 733.	2.0	60
164	Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 575-584.	1.1	104
165	Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations?. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 454-464.	1.1	38
166	Drug policy in Europe. <i>Early Human Development</i> , 2011, 87, S27-S30.	0.8	36
167	Antifungal prophylaxis in neonates. <i>Early Human Development</i> , 2011, 87, S59-S60.	0.8	28
168	Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs. <i>Pharmacogenomics</i> , 2011, 12, 827-843.	0.6	13
169	Determination of ciprofloxacin in plasma by micro-liquid chromatography-mass spectrometry: An adapted method for neonates. <i>Biomedical Chromatography</i> , 2011, 25, 827-832.	0.8	22
170	Principles of Therapeutic Drug Monitoring. <i>Handbook of Experimental Pharmacology</i> , 2011, 205, 77-90.	0.9	29
171	Limited Sampling Strategy for Estimating Individual Exposure of Tacrolimus in Pediatric Kidney Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 681-687.	1.0	23
172	Safety of ciprofloxacin in neonates with sepsis. <i>Adverse Drug Reaction Bulletin</i> , 2010, &NA;, 1019-1022.	0.6	2
173	Cost-Effectiveness Analysis of Individualized Mycophenolate Mofetil Dosing in Kidney Transplant Patients in the APOMYGRE Trial. <i>Transplantation</i> , 2010, 89, 1255-1262.	0.5	15
174	Developmental Pharmacogenetics of Immunosuppressants in Pediatric Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 688-699.	1.0	32
175	Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months. <i>Antiviral Therapy</i> , 2010, 15, 297-305.	0.6	26
176	The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 653-658.	1.1	14
177	Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics. <i>Pediatric Nephrology</i> , 2010, 25, 965-969.	0.9	37
178	Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 358-366.	1.1	34
179	Renal transplantation in children: Critical analysis of age related surgical complications. <i>Pediatric Transplantation</i> , 2010, 14, 512-519.	0.5	68
180	Are Cytochrome P450 CYP2C8 and CYP2C9 Polymorphisms Associated with Ibuprofen Response in Very Preterm Infants?. <i>PLoS ONE</i> , 2010, 5, e12329.	1.1	39

#	ARTICLE	IF	CITATIONS
181	Population Pharmacokinetics and Pharmacogenetics of Mycophenolic Acid Following Administration of Mycophenolate Mofetil in De Novo Pediatric Renal Transplant Patients. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 1280-1291.	1.0	61
182	Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: Pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients. <i>Pharmacological Research</i> , 2010, 61, 167-174.	3.1	13
183	Role of echinocandins in the management of fungal infections in neonates. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2010, 23, 49-52.	0.7	16
184	The use of fluconazole in neonatal intensive care units. <i>Archives of Disease in Childhood</i> , 2009, 94, 983-987.	1.0	21
185	Bioavailability of oral vitamin E formulations in adult volunteers and children with chronic cholestasis or cystic fibrosis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2009, 34, 515-522.	0.7	28
186	Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 609-618.	2.3	142
187	Population Pharmacokinetics of Ganciclovir Following Administration of Valganciclovir in Paediatric Renal Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2009, 48, 321-328.	1.6	25
188	Characterization of a novel TPMT mutation associated with azathioprine-induced myelosuppression. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 770-772.	1.1	8
189	mRNA Expression of MDR1 and Major Metabolising Enzymes in Human Fetal Tissues. <i>Drug Metabolism and Pharmacokinetics</i> , 2009, 24, 529-536.	1.1	22
190	Determination of ketamine and norketamine in plasma by micro-liquid chromatography-mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008, 48, 171-176.	1.4	29
191	The DEC-net European register of paediatric drug therapy trials: contents and context. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 611-617.	0.8	6
192	Comparison of high-performance liquid chromatography and enzyme-multiplied immunoassay technique to monitor mycophenolic acid in paediatric renal recipients. <i>Pediatric Nephrology</i> , 2008, 23, 1859-1865.	0.9	23
193	Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease. <i>Haematologica</i> , 2008, 93, 502-510.	1.7	74
194	Rectal acetaminophen does not reduce morphine consumption after major surgery in young infants. <i>British Journal of Anaesthesia</i> , 2007, 98, 372-379.	1.5	78
195	Population Pharmacokinetics and Bayesian Estimator of Cyclosporine in Pediatric Renal Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 96-102.	1.0	38
196	Excretion of Ketoprofen and Nalbuphine in Human Milk During Treatment of Maternal Pain After Delivery. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 815-818.	1.0	34
197	Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2007, 32, 633-639.	0.7	26
198	Presentation of the French Network of Paediatric Clinical Investigation Centres (CIC.P). <i>Fundamental and Clinical Pharmacology</i> , 2007, 21, 105-110.	1.0	7

#	ARTICLE	IF	CITATIONS
199	A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 609-620.	1.1	52
200	Principes de pharmacologie pédiatrique. , 2007, , 22-30.		2
201	Patient Characteristics Influencing Ciclosporin Pharmacokinetics and Accurate Bayesian Estimation of Ciclosporin Exposure in Heart, Lung and Kidney Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2006, 45, 905-922.	1.6	28
202	Pain control: Non-steroidal anti-inflammatory agents. <i>Seminars in Fetal and Neonatal Medicine</i> , 2006, 11, 251-259.	1.1	46
203	Risk Management and Monitoring Methods for the Future Mother, Embryo, Fetus, and post-natal Consequences. <i>Thérapie</i> , 2006, 61, 297-304.	0.6	2
204	Prevention and Management of Pain in Neonates. , 2006, , 409-415.		0
205	Population Pharmacokinetics of Mycophenolic Acid in Kidney Transplant Pediatric and Adolescent Patients. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 378-388.	1.0	54
206	Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2005, 112, 710-712.	1.1	68
207	Neonatal seizures associated with maternal hydroxyzine hydrochloride in late pregnancy. <i>Reproductive Toxicology</i> , 2005, 20, 573-574.	1.3	30
208	LOCALIZATION AND mRNA EXPRESSION OF CYP3A AND P-GLYCOPROTEIN IN HUMAN DUODENUM AS A FUNCTION OF AGE. <i>Drug Metabolism and Disposition</i> , 2005, 33, 1603-1607.	1.7	133
209	Bayesian Parameter Estimates of Nelfinavir and Its Active Metabolite, Hydroxy- tert -Butylamide, in Infants Perinatally Infected with Human Immunodeficiency Virus Type 1. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 525-535.	1.4	6
210	Effects of drugs on the fetus. <i>Seminars in Fetal and Neonatal Medicine</i> , 2005, 10, 139-147.	1.1	16
211	Cellular Immune Response of Fetuses to Cytomegalovirus. <i>Pediatric Research</i> , 2004, 55, 280-286.	1.1	41
212	Diclofenac and metabolite pharmacokinetics in children. <i>Paediatric Anaesthesia</i> , 2004, 14, 443-451.	0.6	71
213	Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 89-96.	0.8	72
214	Fetal thyroid goiter after massive iodine exposure. <i>Prenatal Diagnosis</i> , 2004, 24, 751-753.	1.1	11
215	Population pharmacokinetic model for nelfinavir and its active metabolite hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, P15.	2.3	0
216	Pharmacogenetics of CYP3A5 and effects of corticosteroids in children treated for acute lymphoblastic leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, P20.	2.3	0

#	ARTICLE	IF	CITATIONS
217	Ontogeny of cytochrome 3A and P-glycoprotein in the human intestine. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, P50.	2.3	0
218	Immunohistochemical localisation and mRNA quantification of P-gp in human term placentas - no impact of corticosteroid administration for preterm labor. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, P73.	2.3	0
219	Launch of a European paediatric clinical trials register. <i>Paediatric and Perinatal Drug Therapy</i> , 2004, 6, 38-39.	0.6	9
220	Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. <i>Pediatric Nephrology</i> , 2003, 18, 943-948.	0.9	34
221	Population Pharmacokinetics of Ciprofloxacin in Pediatric and Adolescent Patients with Acute Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3170-3178.	1.4	34
222	Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. <i>Pediatric Infectious Disease Journal</i> , 2003, 22, 48-55.	1.1	35
223	Méthodologie de l'évaluation des médicaments chez la femme enceinte. <i>Thérapie</i> , 2003, 58, 247-252.	0.6	2
224	Population Pharmacokinetics of Nalbuphine in Neonates. <i>Paediatric and Perinatal Drug Therapy</i> , 2003, 5, 190-198.	0.6	11
225	Intravesical Morphine Analgesia Is Not Effective After Bladder Surgery in Children: Results of A Randomized Double-Blind Study. <i>Journal of Urology</i> , 2002, 168, 694-697.	0.2	14
226	Maternal smoking during pregnancy and nicotine and cotinine concentrations in maternal and neonatal hair. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2002, 109, 909-911.	1.1	42
227	Risks and Benefits of Nonsteroidal Anti-Inflammatory Drugs in Children. <i>Paediatric Drugs</i> , 2001, 3, 817-858.	1.3	133
228	Intravenous Omeprazole in Children: Pharmacokinetics and Effect on 24-Hour Intragastric pH. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2001, 33, 144-148.	0.9	31
229	Quantification of busulfan in plasma by liquid chromatography-ion spray mass spectrometry. <i>Biomedical Applications</i> , 2001, 763, 61-69.	1.7	31
230	Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1397-1402.	1.9	59
231	Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine. <i>Leukemia</i> , 2001, 15, 1706-1712.	3.3	35
232	Pathologic and laboratory correlation in microcephaly associated with prenatal cocaine exposure. <i>Early Human Development</i> , 2001, 63, 79-81.	0.8	10
233	Cotrimoxazole for Prenatal Treatment of Congenital Toxoplasmosis?. <i>Parasitology Today</i> , 2000, 16, 254-256.	3.1	28
234	Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. <i>Pediatric Nephrology</i> , 2000, 14, 95-99.	0.9	51

#	ARTICLE	IF	CITATIONS
235	Monitoring azathioprine therapy in pediatric renal transplant patients with red blood cell thiopurine methyltransferase. Transplantation Proceedings, 2000, 32, 361-363.	0.3	3
236	High-performance liquid chromatographic method for quantification of busulfan in plasma after derivatization by tetrafluorothiophenol. Biomedical Applications, 1999, 721, 147-152.	1.7	33
237	Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine. British Journal of Clinical Pharmacology, 1999, 48, 793-800.	1.1	46
238	CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype. British Journal of Clinical Pharmacology, 1999, 47, 121-124.	1.1	30
239	Monitoring Azathioprine Therapy in Paediatric Renal Transplant Recipients with Thiopurine Methyltransferase. Pediatric Research, 1999, 45, 65A-65A.	1.1	0
240	Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. European Journal of Clinical Pharmacology, 1998, 54, 555-560.	0.8	19
241	Quantification of busulfan in plasma by gas chromatography-mass spectrometry following derivatization with tetrafluorothiophenol. Biomedical Applications, 1998, 709, 47-56.	1.7	31
242	Pharmacokinetics and distribution of 6-mercaptopurine administered intravenously in children with lymphoblastic leukaemia. European Journal of Clinical Pharmacology, 1997, 53, 71-74.	0.8	25
243	Thiopurine methyltransferase activity: new high-performance liquid chromatographic assay conditions. Biomedical Applications, 1997, 700, 275-277.	1.7	14
244	Pharmacokinetics of the S(+) and R(â”) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. British Journal of Clinical Pharmacology, 1997, 44, 183-185.	1.1	18
245	Assessment of CYP2D6 activity in very elderly healthy subjects. Fundamental and Clinical Pharmacology, 1996, 10, 158-159.	1.0	5
246	Clinical Pharmacokinetics of Sedatives in Neonates. Clinical Pharmacokinetics, 1996, 31, 423-443.	1.6	82
247	Nomenclature for human CYP2D6 alleles. Pharmacogenetics and Genomics, 1996, 6, 193-201.	5.7	403
248	Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: Comparison of sparteine and dextromethorphan*. Clinical Pharmacology and Therapeutics, 1996, 59, 583-592.	2.3	26
249	Study of the B cell response to cytochrome P450IID6 in sera from chronic hepatitis C patients. Clinical and Experimental Immunology, 1996, 106, 336-343.	1.1	21
250	Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans*. Clinical Pharmacology and Therapeutics, 1995, 58, 257-263.	2.3	14
251	Conformational epitopes on CYP2D6 are recognized by liver/kidney microsomal antibodies. Gastroenterology, 1995, 108, 470-476.	0.6	59
252	GÃ©nÃ©tique molÃ©culaire du cytochrome P450 IID : anomalies du mÃ©tabolisme des mÃ©dicaments. Revue Francaise D'allergologie Et D'immunologie Clinique, 1995, 35, 462-469.	0.1	0

#	ARTICLE	IF	CITATIONS
253	Molecular genetics of cytochrome P450 IID. <i>Clinical Reviews in Allergy and Immunology</i> , 1995, 13, 211-221.	2.9	1
254	Cyclosporine pharmacokinetics in nephrotic and kidney-transplanted children. <i>European Journal of Clinical Pharmacology</i> , 1994, 47, 61-5.	0.8	19
255	Pharmacokinetics of intravenous omeprazole in children. <i>European Journal of Clinical Pharmacology</i> , 1994, 47, 181-5.	0.8	30
256	DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers. <i>Human Genetics</i> , 1994, 94, 401-6.	1.8	29
257	Population pharmacokinetics of midazolam in neonates. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 56, 615-625.	2.3	158
258	Placebo-controlled trial of midazolam sedation in mechanically ventilated newborn babies. <i>Lancet, The</i> , 1994, 344, 646-650.	6.3	120
259	Thiopurine methyltransferase activity in a French population: h.p.l.c. assay conditions and effects of drugs and inhibitors.. <i>British Journal of Clinical Pharmacology</i> , 1994, 38, 1-8.	1.1	55
260	N-acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients [letter]. <i>British Journal of Clinical Pharmacology</i> , 1994, 38, 581-582.	1.1	35
261	DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers. <i>Human Genetics</i> , 1993, 92, 367-372.	1.8	11
262	Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.. <i>British Journal of Clinical Pharmacology</i> , 1993, 35, 161-165.	1.1	7
263	CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. <i>Pharmacogenetics and Genomics</i> , 1993, 3, 197-204.	5.7	132
264	Interspecies variations in caffeine metabolism related to cytochrome P4501A enzymes. <i>Xenobiotica</i> , 1992, 22, 671-680.	0.5	105
265	Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 51, 507-512.	2.3	26
266	Clinical and pharmacologic study of fetal supraventricular tachyarrhythmias. <i>Journal of Pediatrics</i> , 1992, 121, 608-613.	0.9	44
267	Cytochrome P450-Dependent Metabolism of Dextromethorphan: Fetal and Adult Studies. <i>Developmental Pharmacology and Therapeutics</i> , 1992, 18, 161-168.	0.2	38
268	Pharmacokinetics of midazolam during continuous infusion in critically ill neonates. <i>European Journal of Clinical Pharmacology</i> , 1992, 42, 329-32.	0.8	93
269	Pharmacokinetics of ganciclovir in renal transplant children. <i>Pediatric Nephrology</i> , 1992, 6, 194-196.	0.9	11
270	Cytochrome P450-dependent metabolism of dextromethorphan: fetal and adult studies. <i>Developmental Pharmacology and Therapeutics</i> , 1992, 18, 161-8.	0.2	8

#	ARTICLE	IF	CITATIONS
271	Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1992, 263, 780-6.	1.3	27
272	Distinct phenotypes and genotypes of debrisoquine hydroxylation among Europeans and Chinese [letter]. <i>British Journal of Clinical Pharmacology</i> , 1991, 32, 135-136.	1.1	8
273	Hypotension with midazolam and fentanyl in the newborn. <i>Lancet, The</i> , 1991, 337, 1545-1546.	6.3	62
274	Monoclonal antibody fluorescent polarisation immunoassay versus ¹²⁵ Iode labelled ligand radioimmunoassay for the measurement of cyclosporine concentrations in whole blood. <i>Fundamental and Clinical Pharmacology</i> , 1991, 5, 557-562.	1.0	3
275	Cytochrome P450IID subfamily in non-human primates. <i>Biochemical Pharmacology</i> , 1991, 41, 1657-1663.	2.0	16
276	Influence of amiodarone on genetically determined drug metabolism in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 50, 259-266.	2.3	25
277	Expression of CYP2D6 in developing human liver. <i>FEBS Journal</i> , 1991, 202, 583-588.	0.2	180
278	Pharmacokinetics of midazolam in critically ill neonates. <i>European Journal of Clinical Pharmacology</i> , 1990, 39, 191-192.	0.8	96
279	Perinatal adverse effects of nalbuphine given during parturition. <i>Lancet, The</i> , 1990, 335, 1588.	6.3	17
280	Toxic epidermal necrolysis due to paediatric erythromycin/sulfisoxazole combination. <i>Lancet, The</i> , 1990, 336, 1010-1011.	6.3	6
281	Dextromethorphan phenotypes in paediatric patients with autoimmune hepatitis.. <i>British Journal of Clinical Pharmacology</i> , 1990, 30, 153-154.	1.1	9
282	Genetic Polymorphisms of Drug Metabolism. <i>Developmental Pharmacology and Therapeutics</i> , 1989, 13, 78-84.	0.2	4
283	Dextromethorphan phenotypes determined by high-performance liquid chromatography and fluorescence detection. <i>Biomedical Applications</i> , 1989, 495, 361-363.	1.7	17
284	Pharmacokinetics of cefotaxime and desacetylcefotaxime in the newborn. <i>Diagnostic Microbiology and Infectious Disease</i> , 1989, 12, 87-91.	0.8	20